DK1748770T3 - Behandling og forebyggelse af benign brystsygdom med 4-hydroxy-tamoxifen - Google Patents

Behandling og forebyggelse af benign brystsygdom med 4-hydroxy-tamoxifen

Info

Publication number
DK1748770T3
DK1748770T3 DK05716433T DK05716433T DK1748770T3 DK 1748770 T3 DK1748770 T3 DK 1748770T3 DK 05716433 T DK05716433 T DK 05716433T DK 05716433 T DK05716433 T DK 05716433T DK 1748770 T3 DK1748770 T3 DK 1748770T3
Authority
DK
Denmark
Prior art keywords
benign breast
hydroxy tamoxifen
breast disease
prevention
treatment
Prior art date
Application number
DK05716433T
Other languages
Danish (da)
English (en)
Inventor
Nestour Elisabeth Le
Original Assignee
Besins Int Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04290761A external-priority patent/EP1579856A1/en
Priority claimed from US10/805,528 external-priority patent/US7507769B2/en
Application filed by Besins Int Lab filed Critical Besins Int Lab
Application granted granted Critical
Publication of DK1748770T3 publication Critical patent/DK1748770T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK05716433T 2004-03-22 2005-03-10 Behandling og forebyggelse af benign brystsygdom med 4-hydroxy-tamoxifen DK1748770T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290761A EP1579856A1 (en) 2004-03-22 2004-03-22 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US10/805,528 US7507769B2 (en) 2004-03-22 2004-03-22 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
PCT/EP2005/003286 WO2005092309A1 (en) 2004-03-22 2005-03-10 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
DK1748770T3 true DK1748770T3 (da) 2008-08-04

Family

ID=34961912

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05716433T DK1748770T3 (da) 2004-03-22 2005-03-10 Behandling og forebyggelse af benign brystsygdom med 4-hydroxy-tamoxifen

Country Status (17)

Country Link
EP (1) EP1748770B1 (zh)
JP (1) JP5072588B2 (zh)
CN (1) CN1946387B (zh)
AT (1) ATE391499T1 (zh)
AU (1) AU2005227072B2 (zh)
CA (1) CA2559748C (zh)
DE (1) DE602005005986T2 (zh)
DK (1) DK1748770T3 (zh)
ES (1) ES2306111T3 (zh)
HK (1) HK1096595A1 (zh)
MX (1) MXPA06010914A (zh)
NO (1) NO336767B1 (zh)
NZ (1) NZ549817A (zh)
PL (1) PL1748770T3 (zh)
PT (1) PT1748770E (zh)
RU (1) RU2357726C2 (zh)
WO (1) WO2005092309A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1799201T3 (da) * 2004-10-14 2009-03-30 Besins Int Lab 4-Hydroxy-tamoxifen gelformuleringer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2515041A1 (fr) * 1981-10-26 1983-04-29 Besins Jean Medicament a base de progesterone pour le traitement des affections mammaires
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
EP0287690B1 (de) * 1987-04-21 1992-09-02 HEUMANN PHARMA GMBH & CO Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
DK1317921T3 (da) * 2001-12-07 2009-12-21 Besins Mfg Belgium Farmaceutisk sammensætning i form af en gel eller oplösning med dihydrotestosteron, fremgangsmåde til fremstilling og anvendelser heraf
MXPA05006526A (es) * 2002-12-18 2006-02-17 Besins Int Lab Tratamiento de mastalgia con 4-hidroxi tamoxifen.
EP2050443B1 (en) * 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
JP5490346B2 (ja) * 2003-04-01 2014-05-14 ブザン ヘルスケア ルクセンブルグ エスアーエールエル 4−ヒドロキシタモキシフェンによる乳癌の予防および治療
NZ547744A (en) * 2003-12-15 2009-09-25 Besins Int Lab Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia

Also Published As

Publication number Publication date
CA2559748C (en) 2013-05-28
CA2559748A1 (en) 2005-10-06
DE602005005986D1 (de) 2008-05-21
CN1946387B (zh) 2011-08-31
AU2005227072B2 (en) 2010-08-19
EP1748770B1 (en) 2008-04-09
RU2006137280A (ru) 2008-04-27
RU2357726C2 (ru) 2009-06-10
EP1748770A1 (en) 2007-02-07
NO336767B1 (no) 2015-10-26
WO2005092309A1 (en) 2005-10-06
DE602005005986T2 (de) 2009-06-04
AU2005227072A1 (en) 2005-10-06
JP2007535505A (ja) 2007-12-06
ES2306111T3 (es) 2008-11-01
PL1748770T3 (pl) 2008-09-30
HK1096595A1 (en) 2007-06-08
NZ549817A (en) 2010-06-25
NO20064609L (no) 2006-10-11
ATE391499T1 (de) 2008-04-15
MXPA06010914A (es) 2006-12-15
JP5072588B2 (ja) 2012-11-14
CN1946387A (zh) 2007-04-11
PT1748770E (pt) 2008-07-16

Similar Documents

Publication Publication Date Title
NO20054526L (no) Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
NZ746784A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
EA200971053A1 (ru) Способы лечения кожных язв
EA200700273A1 (ru) Способ лечения гиперфосфатемии c использованием гидроксикарбоната лантана
Cohen et al. The bright side of ascites in ovarian cancer
BR112022010806A2 (pt) Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama
CY1118486T1 (el) Λαπατινιμπη για τη θεραπεια του καρκινου
DE60320398D1 (de) Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
RU2017129056A (ru) Антигистаминное средство для применения для лечения рака молочной железы
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
NO20062904L (no) Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti
DK1748770T3 (da) Behandling og forebyggelse af benign brystsygdom med 4-hydroxy-tamoxifen
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
Swapnil et al. Targeted Drug Delivery: A Backbone for Cancer Therapy
Krco et al. Priapism due to solid malignancy
He et al. Priapism as the initial manifestation of a penile and lower limb cutaneous metastasis of prostate adenocarcinoma with low serum PSA level
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
Jham et al. A case of maxillary sinus carcinoma
Struik Improving Treatment Accuracy and Reducing Side Effects of Breast Conserving Therapy to increase patient satisfaction in early stage breast cancer
Rombolà et al. Long-term treatment of hepatocellular carcinoma with sorafenib
BRPI0409870A (pt) uso de irinotecano para tratamento de cáncer de mama resistente
BR112012013719A2 (pt) uso de transferrina no tratamento de ß-talassemias